Extensive basic cellular and animal data strongly support that the immune checkpoint proteins targeted in ICI therapies (CTLA-4, PD-1, PD-L1, and LAG-3) serve as critical negative regulators of atherosclerosis [13, 36, 46]. The gene discussed is CTLA4; the disease is atherosclerosis.